Company / Free Cash Flow
Anixa Biosciences Inc Free Cash Flow History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$5.0M
FY2022
5-year range
-$5.0M / -$4.3M
FY2018-FY2022
Trend
-0.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has declined for 5 consecutive years, from $1M in FY2016 to -$5M in FY2022.
Based on SEC 10-K filings.
-$5M in FY2022.
Declined from -$4M to -$5M over the past 3 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Anixa Biosciences Inc's free cash flow has declined for 5 consecutive years.
- In FY2022, free cash flow decreased 0.8% year-over-year.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -$5.0M | -0.8% |
| FY2020 | -$4.9M | -14.0% |
| FY2019 | -$4.3M | -12.7% |
| FY2018 | -$3.8M | -8.5% |
| FY2017 | -$3.5M | -369.6% |
| FY2016 | $1.3M | +154.8% |
| FY2015 | -$2.4M | - |
| FY2014 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026